This company has been marked as potentially delisted and may not be actively trading. NYSE:ENFN Enfusion (ENFN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisInsider TradesOwnershipTrendsBuy This Stock About Enfusion Stock (NYSE:ENFN) Get Enfusion alerts:Sign Up Key Stats Today's Range$10.76▼$10.7650-Day Range$10.85▼$10.8552-Week Range$7.83▼$11.80VolumeN/AAverage Volume735,304 shsMarket Capitalization$1.39 billionP/E Ratio269.07Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois. Read More Receive ENFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENFN Stock News HeadlinesClearwater Analytics: Q3 Figures Show Enfusion Acquisition Brings Meaningful GrowthNovember 12, 2025 | seekingalpha.comClearwater Analytics reinstated with an Overweight at JPMorganApril 26, 2025 | markets.businessinsider.comJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before major runs - says the window to get in early is closing fast. Brown is showing investors how to claim a stake in Elon Musk's company before it hits the public markets. Once the IPO happens, this pre-public opportunity disappears.June 6 at 1:00 AM | Brownstone Research (Ad)Clearwater Analytics: 3 Acquisitions That Make This A Strong BuyApril 24, 2025 | seekingalpha.comClearwater Analytics Finalizes Acquisition of EnfusionApril 21, 2025 | businesswire.comClearwater Analytics and Enfusion Announce Election Deadline for Enfusion Shareholders to Elect Form of Merger ConsiderationApril 2, 2025 | businesswire.comENFUSION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Enfusion, Inc. - ENFNApril 2, 2025 | businesswire.comEnfusion, Inc.: Enfusion Announces Fourth Quarter and Full Year 2024 ResultsMarch 4, 2025 | finanznachrichten.deSee More Headlines ENFN Stock Analysis - Frequently Asked Questions How were Enfusion's earnings last quarter? Enfusion, Inc. (NYSE:ENFN) issued its earnings results on Monday, March, 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by $0.02. The business had revenue of $52.94 million for the quarter, compared to the consensus estimate of $53.98 million. Enfusion had a trailing twelve-month return on equity of 6.67% and a net margin of 1.70%. When did Enfusion IPO? Enfusion (ENFN) raised $300 million in an initial public offering on Thursday, October 21st 2021. The company issued 18,750,000 shares at $15.00-$17.00 per share. What other stocks do shareholders of Enfusion own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enfusion investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings3/03/2025Today6/06/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorComputer and Technology Industry Prepackaged software Sub-IndustryComputer Software Current SymbolNYSE:ENFN CIK1868912 Webwww.enfusion.com Phone312-253-9800FaxN/AEmployees890Year Founded1997Profitability EPS (Trailing Twelve Months)$0.03 Trailing P/E Ratio269.07 Forward P/E Ratio179.33 P/E Growth1.85Net Income$6.03 million Net Margins1.70% Pretax Margin3.64% Return on Equity6.67% Return on Assets4.86% Debt Debt-to-Equity RatioN/A Current Ratio3.62 Quick Ratio3.62 Sales & Book Value Annual Sales$201.61 million Price / Sales6.88 Cash Flow$0.14 per share Price / Cash Flow78.75 Book Value$0.61 per share Price / Book17.64Miscellaneous Outstanding Shares129,001,000Free Float81,720,000Market Cap$1.39 billion OptionableNo Data Beta0.92 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NYSE:ENFN) was last updated on 6/6/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredHow to get into the SpaceX IPO before June 12Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | SponsoredBUY THIS: Claim a backdoor stake in SpaceX before June 12Marc Chaikin, the Wall Street veteran who spotted Nvidia before a 45,000% run, says there's a simple trade ava...Chaikin Analytics | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enfusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enfusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.